Germany covid-19 vaccine prevention Coronavirus Analysis Germany

Pfizer says its covid vaccine successful in interim analysis from Phase 3 trial

Reading now: 759
www.livemint.com

covid vaccine candidate, BNT162b2, against coronavirus has demonstrated evidence of efficacy against COVID-19 in participants.

This is based on the first interim efficacy analysis conducted on November 8, 2020 by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study."Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis," Pfizer said in a statement.Pfizer and German partner BioNTech SE are the first drugmakers to show successful data from a large-scale clinical trial of a coronavirus vaccine.

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA